Chinese Herbal Formula plus Bevacizumab for Lung Cancer Fluid Buildup
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a combination of a traditional Chinese medicine formula (Xuan Yin Ning) plus a targeted cancer drug (bevacizumab) for people with advanced lung cancer and fluid buildup around the lung. It aims to see if adding the herbal treatment can better control the fluid and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-squamous non-small cell lung cancer and have already tried at least one prior treatment (like chemotherapy).
- You have a moderate to large amount of fluid around one lung that causes symptoms like chest tightness or trouble breathing.
- You are between 18 and 75 years old.
- You are in reasonably good health for your age (able to do light activities and care for yourself).
- You must be willing to have a chest tube placed to drain the fluid and receive study medications.
- Your blood counts, liver, kidney, and clotting function must be within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug given directly into the chest cavity to treat fluid buildup caused by non-small cell lung cancer. It may help ease breathing problems and control the fluid.
This trial tests whether adding bevacizumab (a drug that blocks blood vessel growth) to cisplatin (a standard chemotherapy) is better than cisplatin alone for controlling fluid buildup caused by adenocarcinoma. If you have not had prior treatment for this fluid, you may qualify.
This trial tests a Chinese herbal formula (Xingbai Ji) plus standard chemotherapy and an immunotherapy drug (Sintilimab) for people with advanced lung cancer that lacks common targetable mutations. It's designed for those who haven't had treatment for advanced disease yet.
This trial tests adding the drug Adebrelimab to standard care for people with pancreatic cancer that has caused fluid buildup around the lungs or in the belly (called pleural or peritoneal effusions). The goal is to see if this combination can help control the cancer better.
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
Hear when a new Malignant Pleural Effusions (Mpe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.